PHILADELPHIA, June 20, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the closing of its previously announced underwritten public offering of common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission, including the exercise in full by the underwriters of their option to purchase an additional 525,000 shares from Spark at the public offering price of $45.00 per share, less the underwriting discount. The exercise of the option brought the total number of shares sold in the offering to 4,025,000, consisting of 3,025,000 shares sold by Spark and 1,000,000 shares sold by The Children’s Hospital of Philadelphia Foundation (“CHOP”), and increased the aggregate net proceeds to Spark to approximately $128.0 million, after deducting underwriting discounts and before offering expenses. Spark did not receive any proceeds from the sale of shares by CHOP.
J.P. Morgan Securities LLC, Cowen and Company, LLC and RBC Capital Markets, LLC acted as book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated and SunTrust Robinson Humphrey, Inc. acted as lead managers for the offering. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by calling (631) 274-2806 or by faxing (631) 254-7140; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Spark Therapeutics
Spark Therapeutics, a fully-integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. Spark’s validated platform has successfully delivered gene therapies with proof-of-concept data in the eye and liver. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B and SPK-8011, a preclinical candidate, for hemophilia A.